drugset / Trial / NCT01262586

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

NCT01262586

Phase 3 Completed 24 enrolled Novartis Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.

Timeline

Start
2010-11
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 2 mg
Subject Vildagliptin Other / unclassified 50 mg